Sanofi: completes sale of portfolios to Neuraxpharm

(CercleFinance.com) - On Wednesday Neuraxpharm announced that it has completed the acquisition of two product portfolios for central nervous system disorders, pain and vascular diseases, which were previously owned by Sanofi.


The Spanish-German laboratory said that these two portfolios between them include 17 molecules representing 38 treatments currently marketed in over 50 countries.

This group, which includes Tranxene, Dogmatil and Trental, targets diseases such as depression, anxiety, psychosis, alcoholism and Parkinson's disease.

The financial terms of the deal were not disclosed, but Neuraxpharm previously announced that the acquisition of both these portfolios would enable it to increase its annual revenues to around 600 million euros.


Copyright (c) 2023 CercleFinance.com. All rights reserved.